For the Inventor, By the Inventor

Enter assignee name

Cspc Zhongqi Pharmaceutical Technology (shijiazhuang) Co., Ltd.

USPTO Granted Patents = 31

Forward Citations = 23

Loading Chart...

Loading Chart...

121 inventors (with patents filed for the assignee):

Ying Shi (6 out of 6 patents)

Dongmin Shen (6 out of 7 patents)

Shuhui Chen (5 out of 196 patents)

4. Chunlei Li (5 out of 5 patents)

5. Hanyu Yang (5 out of 5 patents)

6. Caixia Wang (4 out of 4 patents)

7. Qingzhi Gao (4 out of 4 patents)

8. Yi Mi (4 out of 5 patents)

9. Yuxiu Ma (4 out of 4 patents)

10. Yanhui Li (4 out of 8 patents)

11. Jian Li (3 out of 199 patents)

12. Song Wu (3 out of 20 patents)

13. Li Zhang (3 out of 5 patents)

14. Min Liang (3 out of 3 patents)

15. Yongfeng Li (3 out of 3 patents)

31 patents: Sort by Forward Citations

1. 12398138 - FGFR inhibitor compound in solid form and preparation method therefor (2025-08-26),

2. 12358925 - Targeted ubiquitination degradation BRD4 protein compound, preparation method therefor and application thereof (2025-07-15),

3. 12344620 - BRD4 inhibitor compound in solid form and preparation method therefor and use thereof (2025-07-01),

4. 12215098 - Solid form, crystalline form, and crystal form a of FXR agonist, and preparation method and application thereof (2025-02-04),

5. 12195471 - Salt of aldose reductase inhibitor, and preparation method and application thereof (2025-01-14),

6. 12024494 - Salt of LSD1 inhibitor and a polymorph thereof (2024-07-02),

7. 11981669 - 1,7-naphthyridine derivative and preparation method and use therefor (2024-05-14),

8. 11583508 - Use of mitoxantrone liposome for treating non-Hodgkin's lymphoma (2023-02-21),

9. 11357728 - Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt (2022-06-14),

10. 11339147 - Lactam compound as FXR receptor agonist (2022-05-24),

11. 11312726 - Thienodiazepine derivatives and application thereof (2022-04-26),

12. 11130761 - Substituted pyrrolo[2,1-f][1,2,4]triazines as FGFR inhibitors (2021-09-28),

13. 10774079 - Quinazoline derivative (2020-09-15),

14. 10550073 - Benzamide derivative (2020-02-04),

15. 10500165 - Purified therapeutic nanoparticles and preparation methods thereof (2019-12-10),

CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. is a leading pharmaceutical company based in Shijiazhuang, China. They specialize in the research, development, production, and marketing of various high-quality pharmaceutical products. With a strong focus on technological innovation and quality assurance, CSPC Zhongqi Pharmaceutical Technology aims to provide safe and effective medications to improve human health. Visit their website to learn more about their products and services.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

31 Patents

#2 in Hebei

#899 in China

#20,624 in the World

Cspc Zhongqi Pharmaceutical Technology (shijiazhuang) Co., Ltd.

Forward Citations = 23

121 inventors:

Ying Shi (6 out of 6 patents)

Dongmin Shen (6 out of 7 patents)

Shuhui Chen (5 out of 196 patents)

4. Chunlei Li (5 out of 5 patents)

5. Hanyu Yang (5 out of 5 patents)

Please report any incorrect information to support@idiyas.com

Loading…